Tradestie Institutional Equity Comparison Engine
SYK vs DXCM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DXCM Overall Edge
DXCM Captures Institutional Edge (3โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DexCom, Inc. (DXCM) driven by superior Valuation, Growth & Margin, Momentum & Technical while SYK counters with relative strength in Options & Structure. Fundamentally, SYK trades at 19.0x Forward P/E with 24.0% operating margin (+7.6% YoY revenue) versus DXCM at 26.6x Forward P/E and 24.0% operating margin (+11.2% YoY). In options structure, SYK sits in SURGE (5th %ile IV; Dealer Gamma Walls on Pro) against DXCM sits in CONSOLIDATION (9th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
DXCM
SYK 19.0x vs DXCM 26.6x Fwd P/E
Growth & Margin Winner
DXCM
Op Margin 24.0% vs 24.0% ยท YoY +7.6% vs +11.2%
Momentum & Technical Winner
DXCM
1Y -16.8% vs +36.6% ยท 52W Pos 36% vs 69%
Options & Structure Winner
SYK
SURGE (5th %ile IV) vs CONSOLIDATION (9th %ile IV)
SYK
NYSE
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap
$118.9B
1M Return
+5.47%
1Y Return
-16.77%
Forward P/E
19.0x
Unified AI Score
46.5 / 100
HOLD
Tech 37.0
Fund 49.0
Flow 58.0
Mom 60.0
DXCM
NASDAQ
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$81.58
-2.11% 1D
Market Cap
$30.4B
1M Return
-5.19%
1Y Return
+36.6%
Forward P/E
26.6x
Unified AI Score
53.8 / 100
HOLD
Tech 74.0
Fund 67.0
Flow 68.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SYK -16.77%
DXCM +36.6%
Spread: +53.37 pp (DXCM Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SYK Revenue | DXCM Revenue | SYK Op. Margin | DXCM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $13.6B | $1.03B | 18.7% | -18.1% | SYK |
| FY2019 | $14.9B | $1.48B | 18.2% | 9.6% | SYK |
| FY2020 | $14.3B | $1.93B | 15.5% | 15.5% | Tie |
| FY2021 | $17.1B | $2.45B | 15.1% | 10.9% | SYK |
| FY2022 | $18.4B | $2.91B | 15.4% | 13.4% | SYK |
| FY2023 | $20.5B | $3.62B | 19.0% | 16.5% | SYK |
| FY2024 | $22.6B | $4.03B | 16.3% | 14.9% | SYK |
| FY2025 | $25.1B | $4.66B | 19.5% | 19.6% | DXCM |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SYK | DXCM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $118.9B | $30.4B | Larger Scale | SYK |
| Trailing P/E Ratio Valuation | 33.3x | 32.0x | Lower Multiple | DXCM |
| Forward P/E Ratio Valuation | 19.0x | 26.6x | Lower Multiple | SYK |
| Revenue Growth (YoY) Growth | +7.6% | +11.2% | Higher Growth | DXCM |
| Operating Margin (TTM) Profitability | 24.0% | 24.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 13.8% | 19.4% | Higher Margin | DXCM |
| Return on Equity (ROE) Capital Efficiency | 16.0% | 37.7% | Higher ROE | DXCM |
| 52-Week Range Position Momentum | 36% ($267โ$389) | 69% ($57โ$93) | Stronger Trend | DXCM |
| Beta / 30D Volatility Risk Regime | 0.22ฮฒ ยท 50% Vol | 0.61ฮฒ ยท 49% Vol | Lower Realized Risk | DXCM |
| Unified Institutional Score Composite Signal | 46.5 / 100 (HOLD) | 53.8 / 100 (HOLD) | Higher Composite | DXCM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SYK vs DXCM Buy Guide
SYK
SURGE
8d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
DXCM
CONSOLIDATION
69d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SYK nor DXCM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.